According to the Phase 2 data for NeoCart ACTI, which was presented at the American Orthopaedic Society for Sports Medicine Annual Meeting, patients with knee cartilage injury who were treated with NeoCart reported better outcomes at the six and 12 month follow-ups than patients who underwent microfracture.
NeoCart is a bio-engineered neo-cartilage implant containing autologous chondrocyte population matured in a biodegradable collagen matrix.
Read the report on NeoCart.
Related Articles on Cartilage Repair:
Dr. Brian Cole: Developing the Future of Cartilage Regeneration in Orthopedics
U.S. Cartilage Repair Market to Grow 6.8% Over Next 4 Years
Northwestern Researchers Develop Nanofiber Gel That May Promote Growth of New Cartilage
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
